Nebula Research & Development LLC Cullinan Oncology, Inc. Transaction History
Nebula Research & Development LLC
- $852 Billion
- Q4 2024
A detailed history of Nebula Research & Development LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 43,702 shares of CGEM stock, worth $350,490. This represents 0.06% of its overall portfolio holdings.
Number of Shares
43,702
Previous 34,537
26.54%
Holding current value
$350,490
Previous $578 Million
7.93%
% of portfolio
0.06%
Previous 0.07%
Shares
4 transactions
Others Institutions Holding CGEM
# of Institutions
152Shares Held
67MCall Options Held
41.1KPut Options Held
112K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$61.3 Million13.93% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$46.1 Million2.62% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$28.5 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$27.4 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$27.1 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $366M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...